REQUEST A DEMO
Total
USD $0.00
Search more companies

SL Therapeutics, Inc. (South Korea)

Main Activities: Research and Development in Nanotechnology
Full name: SL Therapeutics, Inc. Profile Updated: July 28, 2025
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English Download a sample report

The Company is a Korea-based company mainly engaged in the maintenance services of electronic medical machines. The Company operates its business through two segments. The Electronic Medical Machine Business segment is involved in provision of the maintenance services of electronic medical machines, as well as bone mineral densitometers (BMDs) and magnetic resonance imaging (MRI) equipments. The Bio Business segment is engaged in the biotechnology research, as well as the development and sale of stem cell therapies. The stem cell therapies are cell therapies for treating patients with spinal cord injury, multiple sclerosis and multiple system atrophy. The Company was founded on July 08, 2011 and its shares are listed on KOREA NEW EXCHANGE(KONEX) on November 29, 2016.

Headquarters
711 Techno Complex Of Korea University 145 Anam-Dong, Sungbuk-Gu, Seoul 136-701, Korea
Seoul; Seoul;

Contact Details: Purchase the SL Therapeutics, Inc. report to view the information.

Website: http://www.stemlab.co.kr

Basic Information
Total Employees:
Purchase the SL Therapeutics, Inc. report to view the information.
Outstanding Shares:
Purchase the SL Therapeutics, Inc. report to view the information.
Financial Auditors:
Purchase the SL Therapeutics, Inc. report to view the information.
Incorporation Date:
December 06, 2025
Key Executives
Purchase this report to view the information.
Chief Executive Officer
Subsidiaries
㈜스템랩
Company Performance
Financial values in the chart are available after SL Therapeutics, Inc. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency KRW. Absolute financial data is included in the purchased report.
Net sales revenue
89.66%
Total operating revenue
-43.76%
Operating profit (EBIT)
57.51%
EBITDA
34.31%
Net Profit (Loss) for the Period
62.52%
Total assets
-34.82%
Total equity
-18.67%
Operating Profit Margin (ROS)
667.47%
Net Profit Margin
845.85%
Return on Equity (ROE)
-152.03%
Debt to Equity Ratio
20.07%
Quick Ratio
-0.08%
Cash Ratio
-0.09%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?